Merck’s remigromig meets primary endpoint in diabetic macular edema trial
publishers 5articles 5first reported 24 Sep, 12:15 UTCdeveloping since 25 Sep · 2 editions
Merck said remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO study of adults with diabetic macular edema. The experimental drug is a tri-specific agonist of the Wingless-related integration site, or Wnt, pathway.
Endpoints News described the result as a first success for Merck’s return to ophthalmology. FirstWord reported that safety concerns emerged in the study.
HOW THIS STORY WAS MADE
Written from 5 articles, headlines and summaries only; 5 independent newsrooms once syndicated copies count as one; this version written within the hour the record first saw the story; the editor revised it.
- Publishers
- 5
- Source articles
- 5
- Given to the writer
- 5, headlines and summaries only
- Independent newsrooms
- 5
- This version written
- within the hour the record first saw the story
- Second model (editor)
- revised
- Publication gate
- passed
- Human review
- none
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →